![世衛(wèi)組織2023 年擴(kuò)大免疫計(jì)劃 (-EPI)- 資料表:東帝汶_第1頁](http://file4.renrendoc.com/view5/M00/26/15/wKhkGGYhzzqABm4uAAIYlTbGA_c864.jpg)
![世衛(wèi)組織2023 年擴(kuò)大免疫計(jì)劃 (-EPI)- 資料表:東帝汶_第2頁](http://file4.renrendoc.com/view5/M00/26/15/wKhkGGYhzzqABm4uAAIYlTbGA_c8642.jpg)
![世衛(wèi)組織2023 年擴(kuò)大免疫計(jì)劃 (-EPI)- 資料表:東帝汶_第3頁](http://file4.renrendoc.com/view5/M00/26/15/wKhkGGYhzzqABm4uAAIYlTbGA_c8643.jpg)
![世衛(wèi)組織2023 年擴(kuò)大免疫計(jì)劃 (-EPI)- 資料表:東帝汶_第4頁](http://file4.renrendoc.com/view5/M00/26/15/wKhkGGYhzzqABm4uAAIYlTbGA_c8644.jpg)
![世衛(wèi)組織2023 年擴(kuò)大免疫計(jì)劃 (-EPI)- 資料表:東帝汶_第5頁](http://file4.renrendoc.com/view5/M00/26/15/wKhkGGYhzzqABm4uAAIYlTbGA_c8645.jpg)
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
Year
Milestone
1978
2000
2007
2012
2016
2016
2016
2016
2016
2016
2019
EPIstarted
EPIre-structuredinMarch
DTP-HepBvaccineintroduced
DTP-Hib-HepBvaccineintroduced
MRvaccineintroducedinFeb
SeconddoseofMRintroducedinFeb
HepBbirthdoseintroducedinFeb
DPT/DTvaccine(boosterdose)introducedinFeb
IPVintroducedinFeb
tOPVtobOPVswitchedon18April
RotavirusvaccineintroducedinDec
Source:cMYP2016-2022andEPI/MOH
Disclaimer:Theboundariesandnames
shownandthedesignationsusedonallthemapsdonotimply
theexpressionofanyopinion
whatsoeveronthepartofthe
WorldHealthOrganization
concerningthelegalstatusofanycountry,territory,cityorareaorofitsauthorities,orconcerning
thedelimitationofitsfrontiersorboundaries.
FACTSHEET2023
TIMORLESTE
EXPANDEDPROGRAMMEONIMMUNIZATION(EPI)
Table1:EPIHistory
Table2:Basicinformation2022
Totalpopulation1
Livebirths1
Children<1year1
Children<5years1
Children<15years1
Pregnantwomen1
WCBA1(15-49years)
Neonatalmortalityrate2
Infantmortalityrate2
Under-fivemortalityrate2
Maternalmortalityratio2
Division/Province/State/Region
Municipality
Postos/Sub-district
Sucos/Village
Populationdensity1(persq.km)
Populationlivinginurbanareas2
Populationusingatleastbasicdrinking-waterservices2
Populationusingatleastbasicsanitationservices2
Totalexpenditureonhealthas%ofGDP2BirthsattendedbyskilledhealthpersonnelNeonatesprotectedatbirthagainstNT2Childrennotcoveredbyimmunization
programme(zerodosechildren)3
1,318,445
31,832
31,832
157,324
474,368
36,586
332,107
22.23(per1,000LB)43.08(per1,000LB)50.55(per1,000LB)204(per100,000LB)
13
13
72
452
89
35.80%
87%
58%
5.45%
57%
83%
4,184
1SEARannualEPIreportingform,2022
2WHO,GlobalHealthObservatory(GHO)data
/gho/dataaccessedon03August2023
3DTP1coveragefromWHOandUNICEFestimatesof
immunizationcoverageandUNestimatedunderonepopulation
Figure1:Nationalimmunizationcoverage,2013-2022
Source:WHOandUNICEFestimatesofimmunizationcoverage
Table3:Immunizationschedule,2022
Vaccine
Ageofadministration
BCG
HepB
DTP-Hib-HepB
OPV
IPV
MR
Td
DT
DTP
Rotavirus
VitaminA
Birth
Birthwithin24hours
6weeks,10weeksand14weeks
Birth,6weeks,10weeksand14weeks
14weeks
9monthsand18months
Females15to49years(1stpregnancycontact,+1months,+6months,
+1year,+1year)
6years
18months
6weeks,10weeksand14weeks
6-36months(with6monthsinterval)
Source:WHO/UNICEFJRF,2022
Table4:Immunizationsystemhighlights
cMYPforimmunization
NITAG-TL
Spendingonvaccinesfinancedbythegovernment
Spendingonroutine
immunizationprogrammefinancedbythegovernment
Updatedmicro-plansthatincludeactivitiestoimproveimmunizationcoverage
Nationalpolicyforhealthcarewastemanagementincludingwastefromimmunization
activities
NationalsystemtomonitorAEFI
MostrecentEPICES
>80%coverageforDTP-Hib-HepB3
>90%coverageforMCV1
>90%coverageforMCV2
>10%drop-outrateforDTP-Hib-HepB1toDTP-Hib-HepB3
2016-2022
fullyfunctional
100%
64%
13districts(100%)
inplace
inplace
EPICoveragesurvey2018
13districts(100%)
5districts(38%)
4districts(31%)
5districts(36%)
Source:WHO/UNICEFJRF,2022
WorldHealthOrganization?SEARO/CDS/IVD?31October2023
Figure2:DTP3coverage1,diphtheriaandpertussiscases2,1980-2022
Figure3:TT2+coverage1andNTcases2,1980-2022
1
2
WHOandUNICEFestimatesofimmunizationcoverage
WHOvaccine-preventablediseases:monitoringsystem2022
1Countryofficialestimates,1980-2022
2WHOvaccine-preventablediseases:monitoringsystem2022
DTP-Hib-HepB3coveragebydistrict
Figure4:2021
Figure5:2022
<70%70%-79%80%-89%>90%
Source:SEARannualEPIreportingform,2021and2022(administrativedata)
Table5:Reportedcasesofvaccinepreventablediseases,2016-2022
Year
Polio
Diphtheria
Pertussis
NT(%ofall
tetanus)
Measles
Rubella
Mumps
JE
CRS
2016
0
0
6
0
2
8
0
1
0
2017
0
0
1
1(100%)
0
3
21
7
0
2018
0
0
0
1(100%)
0
8
26
0
0
2019
0
0
7
0
22*
21
ND
23
0
2020
0
0
5
2(100%)
2
5
0
0
0
2021
0
0
0
ND
3
4
0
ND
0
2022
0
0
0
1(50%)
8
41
0
1
0
Source:WHO/UNICEFJRF(multipleyears)*Imported/ImportrelatedND=Nodata
Table6:AFPsurveillanceperformanceindicators,2016-2022
?ThelastlaboratoryconfirmedpoliocaseduetoWPVwasreportedinNovember1993
Indicator
2016
2017
2018
2019
2020
2021
2022
AFPcases
10
5
0
5
1
0
0
Wildpoliovirusconfirmedcases
0
0
-
0
0
-
-
Compatiblecases
0
0
-
0
0
-
-
Non-polioAFPrate1
2.16
1.08
-
0.83
0.21
-
-
Adequatestoolspecimencollectionpercentage2
0.5
60%
-
0.2
0%
-
-
Totalstoolsamplescollected
-
8
-
2
1
-
-
%NPEVisolation
-
13
-
0
0
-
-
%Timelinessofprimaryresultreported3
-
100
-
100
100
-
-
1NumberofdiscardedAFPcasesper100,000childrenunder15yearsofage.
2Percentwith2specimens,24hoursapartandwithin14daysofparalysisonset.
3Resultsreportedwithin14daysofsamplereceivedatlaboratory.
Non-polioAFPratebydistrict
Figure6:2021
Adequatestoolspecimencollection%bydistrict
Figure8:2021
NoAFPcasereported
NoAFPcasereported
Figure7:2022
Figure9:2022
NoAFPcasereported
NoAFPcasereported
<11–1.99>2Nonon-polioAFPcase<60%60%-79%>80%NoAFP
Table7:OPVSIAs
Year
Antigen
Geographiccoverage
Targetage
Targetpopulation
Coverage(%)
Round1
Round2
Round1
Round2
2005
2015*
2018*
2020
OPV
OPV
OPV
OPV
NID
NID
NID
<5
<5
<5
years
years
years
177,713
522,943
165,013
93
96
111
-
102
-
-
-
Source:WHO/UNICEFJRF(multipleyears)
VACCINESPROTECT
SUSTAIN.ACCELERATE.INNOVATE.
Figure10:HepB3andHepBbirthdoseimmunizationcoverage1,2000-2022
Figure11:MCV1&MCV2coverage1andmeasles,rubellacases2,1980-2022
1
WHOandUNICEFestimatesofimmunizationcoverage
1WHOandUNICEFestimatesofimmunizationcoverage
2WHOvaccine-preventablediseases:monitoringsystem2022
MR1coveragebydistrict
MR2coveragebydistrict
Figure12:2021
Figure14:2021
Figure13:2022
Figure15:2022
<80%80%-89%90%-94%>95%
Source:SEARannualEPIreportingform,2021and2022(administrativedata)
Table8:MCV/MRSIAs
Year
Antigen
Geographiccoverage
Targetgroup
Target
Coverage%
2003
M
nationwide
9to59months
128,318
99
2006
M
nationwide
6monthsto14years
390,687
40
2009
M
nationwide
9to59months
167,136
76
2011
M
nationwide
6monthsto14years
494,427
92
2015
MR
nationwide
6monthsto14years
501,832
97
2018
MR
nationwide
6to59months
142,935
110
Source:WHO/UNICEFJRF(multipleyears)
WorldHealthOrganization?SEARO/CDS/IVD?31October2023
Figure16:Immunityagainstmeasles-immunityprofilebyagein2022*
*ModelledusingMSPtoolver2
Figure17:Immunityagainstrubellathroughvaccination-immunityprofilebyagein2022*
*ModelledusingWHOandUNICEFestimatesandJRF(multipleyears)anddoesnotincludeimmunityduetonaturalinfection
Figure18:Confirmedmeaslescases*bymonth2020-2022
*Includeslaboratoryconfirmed,epidemiologicallylinkedandclinicallycompatiblecasesSource:SEARmeaslescase-baseddata
Figure19:Confirmedrubellacases*bymonth2020-2022
*Includeslaboratoryconfirmedandepidemiologicallylinkedcases
Source:SEARmeaslescase-baseddata
andimmunizationmedicalofficersandlaboratories
NationalHealthLaboratory,Dili
?Nationalmeaslesandrubellalaboratory
?NationalJapaneseencephalitislaboratory
VACCINESPROTECT
SUSTAIN.ACCELERATE.INNOVATE.
Figure20:Vaccinationstatusofconfirmed(laboratory,Epilinkedandclinicallycompatible)measlescases,byagein2021and2022
Source:SEARmeaslescase-baseddata
Figure21:Vaccinationstatusofconfirmed(laboratoryandEpilinked)rubellacases,byagein2021and2022
Source:SEARmeaslescase-baseddata
Table9:Summaryofmeaslessurveillanceindicators,2020-2022
Figure22:NetworkofWHOsupportedsurveillance
Indicator
Target
2020
2021
2022
Numberofsuspectedmeaslescases
109
43
47
Confirmedmeaslescases
0
4
3
0
Labconfirmed
0
0
0
0
Epi-Linked
0
0
0
0
Clinically-compatible
0
4
3
0
Confirmedrubellacases
0
5
4
0
Labconfirmed
0
5
2
0
Epi-Linked
0
0
2
0
Discardednon-measlesnon-rubellacases
100
38
47
Percentageofsuspectedcaseswithadequateinvestigationinitiatedwithin48hoursofnotification
≥80%
ND
100
100
Reportingrateofnon-measlesnon-rubellacasestonationallevelper100,000population
≥2
ND
0.83
6.1
Percentageofsecond-leveladministrativeunitsreportingat
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 現(xiàn)代產(chǎn)品設(shè)計(jì)中的民族圖案與色彩研究
- 現(xiàn)代紋樣設(shè)計(jì)在商業(yè)品牌推廣中的應(yīng)用實(shí)踐
- 現(xiàn)代辦公環(huán)境下的AI餐廳服務(wù)應(yīng)用研究
- 現(xiàn)代物流行業(yè)的服務(wù)創(chuàng)新與升級(jí)
- 現(xiàn)代辦公環(huán)境下的報(bào)告制作技巧
- 2024年五年級(jí)語文上冊(cè) 第六單元 口語交際:父母之愛說課稿 新人教版
- Module7 Unit2 This little girl can't walk(Period 1) (說課稿) -2024-2025學(xué)年外研版(三起)英語五年級(jí)上冊(cè)
- 7《什么比獵豹的速度更快》說課稿-2024-2025學(xué)年五年級(jí)上冊(cè)語文統(tǒng)編版001
- 13美麗的冬天 說課稿-2024-2025學(xué)年道德與法治一年級(jí)上冊(cè)統(tǒng)編版
- 2024-2025學(xué)年高中化學(xué) 第1章 第4節(jié) 第2課時(shí) 有機(jī)物分子式與分子結(jié)構(gòu)的確定說課稿 新人教版選修5
- 提高數(shù)學(xué)教師命題能力培訓(xùn)
- 數(shù)字證書使用承諾函
- 獵聘網(wǎng)在線人才測(cè)評(píng)題庫
- 《社區(qū)康復(fù)》課件-第八章 視力障礙患者的社區(qū)康復(fù)實(shí)踐
- 透析患者的血糖管理
- 瀝青拌合站講義課件
- 《逆向建模與產(chǎn)品創(chuàng)新設(shè)計(jì)》課程標(biāo)準(zhǔn)
- 前置審方合理用藥系統(tǒng)建設(shè)方案
- 人教高中生物必修1第三章細(xì)胞核-系統(tǒng)的控制中心課件25張
- 2022年甘肅省蘭州市診斷考試(一診)數(shù)學(xué)試題(含答案解析)
- 裝載機(jī)裝車施工方案
評(píng)論
0/150
提交評(píng)論